不眠症と持続的な痛みを持つ患者のための"SleepWell"介入:認知行動群療法プログラムのランダム化待合者リスト制御試験のための試験プロトコル
Jan H Rosenvinge1, Svein Bergvik1, Karin Abeler2
1Faculty of Health Sciences, Department of Psychology, UiT - The Arctic University of Norway, 9037, Tromsø, Norway.
Trials
|August 27, 2025
まとめ
不眠症に対する認知行動療法 (CBT-i) は慢性的な痛みや不眠症の患者にとって有望である. この研究は,CBT-iを評価しています.
科学分野:
- 痛みの管理
- 睡眠医学
- 心理学的介入
背景:
- 持続的な痛みと不眠症は しばしば共存し 症状が悪化するサイクルを作り出し 日常生活に影響を及ぼします
- この併発症は鬱や疲労と関連しており 効果的な治療の必要性を強調しています
- 不眠症に対する認知行動療法 (Cognitive Behavioral Therapy for Insomnia) (CBT-i) は睡眠障害に対して有効ですが,併発性疼痛患者での使用は十分に研究されていません.
研究 の 目的:
- 併発性持続性疼痛の患者におけるCBT-iの核心的な不眠症の改善の有効性を評価する.
- 痛みの強度,うつ病,疲労,痛みの受け入れ,生活の質を含む二次的なアウトカムに対するCBT-iの影響を評価する.
- CBT-iの実現可能性と受容性に関する患者の経験を調査し,治療効果の潜在的なメディエーターを特定する.
主な方法:
- 慢性的な痛みと不眠症と診断された106人の入院患者を対象としたランダム化比較試験 (DSM-5)
- 参加者は10週間にわたってグループベースのCBT-iまたは通常の治療 (TAU) にブロックランダム化されます.
- 4ヶ月と12ヶ月でフォローアップ評価を行い,治療意図の原則を用いてデータを分析します. 患者さんの経験はテーマごとに分析されます.
主要な成果:
- * (研究が進行中/最近登録されたため,結果はまだ入手できません) *
- *予想される結果は,睡眠開始の改善,覚醒の減少,睡眠効率の向上,昼間の障害の減少に焦点を当てます. やってみよう
- * 2次結果分析では,痛み,うつ,疲労,痛み受容,生活の質の変化が検討されます. やってみよう
結論:
- この研究は,併発性不眠症と非悪性疼痛の患者に対する適応CBT-iの有効性に関する知識の空白を埋めることを目的としています.
- ポジティブな結果は,睡眠障害を患う体内の病院患者の日常的なケアに心理的な睡眠介入を統合することを支持する可能性がある.
- これらの発見は,この複雑な患者集団の管理のための臨床的勧告を基にすることができる.
関連する概念動画
Insomnia
124
Insomnia is a prevalent sleep disorder characterized by difficulty falling asleep, frequent awakenings during the night, and waking up too early without being able to return to sleep. People with insomnia often experience these disruptions at least three nights a week for at least one month. Chronic insomnia, which lasts for at least three months, can lead to increased anxiety, which in turn can worsen sleep difficulties, creating a cycle of sleeplessness and stress.
Multiple factors contribute...
Multiple factors contribute...
124
Management of Insomnia
320
The sleep cycle, an integral part of human health, consists of several stages with distinct characteristics and functions. It begins with a transition from wakefulness to sleep, known as the light sleep phase, followed by the restorative deep sleep phase, essential for physical recovery and growth. The cycle concludes with the Rapid Eye Movement (REM) phase, characterized by high brain activity and vivid dreaming. Insomnia, a prevalent sleep disorder, involves difficulty falling asleep, staying...
320
Blind Procedures
12.1K
Ideally, the people who observe and record the children’s behavior are unaware of who was assigned to the experimental or control group, in order to control for experimenter bias. Experimenter bias refers to the possibility that a researcher’s expectations might skew the results of the study. Remember, conducting an experiment requires a lot of planning, and the people involved in the research project have a vested interest in supporting their hypotheses. If the observers knew which...
12.1K
Sedatives and Hypnotics Drugs: Miscellaneous Agents
238
Sedatives and hypnotics encompass a wide range of substances, each with its unique mechanism of action, uses, and potential adverse effects.
Melatonin congeners like ramelteon (Rozerem) and tasimelteon (Hetlioz) selectively bind to melatonin receptors (MT1 and MT2) and thus mimic the actions of melatonin, a hormone that regulates sleep-wake cycles. Tasimelteon is primarily used for non-24-hour sleep-wake disorder, common in blind patients. They are also used to treat conditions like insomnia...
Melatonin congeners like ramelteon (Rozerem) and tasimelteon (Hetlioz) selectively bind to melatonin receptors (MT1 and MT2) and thus mimic the actions of melatonin, a hormone that regulates sleep-wake cycles. Tasimelteon is primarily used for non-24-hour sleep-wake disorder, common in blind patients. They are also used to treat conditions like insomnia...
238
CNS Depressants: Barbiturates and Benzodiazepines
466
CNS depressants include drugs from the category of barbiturates and benzodiazepines. They are valuable medications for managing anxiety disorders and insomnia. Barbiturates, once used to induce and maintain sleep, have been replaced mainly by benzodiazepines due to barbiturate's toxicity, tolerance, and overdose risks. They interact with GABAA receptors, leading to sedation at low doses and potentially coma and death at higher doses. Phenobarbital, a long-acting barbiturate, possesses...
466
Sedatives and Hypnotics: Overview
636
Sedatives are drugs that alleviate anxiety, while hypnotics induce sleep. Both classes of medication suppress neuronal activity, leading to a calming effect for sedatives and facilitating sleep for hypnotics.
Sedative-hypnotics are categorized into barbiturates, benzodiazepines (BZDs), and non-benzodiazepines or Z-drugs. These drugs work by suppressing central nervous system activity, and this suppression is dose-dependent. Older sedative medications, like barbiturates, follow a linear curve in...
Sedative-hypnotics are categorized into barbiturates, benzodiazepines (BZDs), and non-benzodiazepines or Z-drugs. These drugs work by suppressing central nervous system activity, and this suppression is dose-dependent. Older sedative medications, like barbiturates, follow a linear curve in...
636


